New prostate cancer drugs can give an extra 2 years to men
International trials of new drugs conducted in part by Northwestern University and Massachusetts General both succeeded in delaying the excruciating and deadly spread of prostate cancer in men.
Condition: High Risk Prostate Cancer Interventions: Diagnostic Test: Whole body contrast enhanced computer tomography; Diagnostic Test: 99mTC-HMDP planar bone scintigraphy (BS); Diagnostic Test: 99mTc-HMDP single photon emission computer tomography/computer tomography; Diagnostic Test: Whole-body magnetic resonance imaging; Diagnostic Test: Fluorine-18-prostate specific membrane antigen-1007- positron emission tomography/computer tomography Sponsors: Turku University Hospital; University of Turku Active, not recruiting
CONCLUSIONS: Afro-Caribbean populations in French West Indies share the same major clinical and pathological risk factors of BCR after RP identified in other ethnic groups. Perioperative blood loss appears to be an additional and independent predictive factor of BCR. LEVEL OF PROOF: 4. PMID: 29789237 [PubMed - as supplied by publisher]
CONCLUSION: A reduction of LUTS is observed in patients with locally advanced or metastatic prostate cancer treated with triptorelin in routine practice. This is in agreement with similar observational studies of triptorelin conducted in other countries. LEVEL OF PROOF: 4. PMID: 29789236 [PubMed - as supplied by publisher]
CONCLUSION: Mp-MRI is a useful exam for selecting patients eligible for AS even if the situation remains unclear after prostate biopsies including targeted biopsies. Upon confirmation by further studies, mp-MRI should be considered as an independent criterion before entering an AS program. LEVEL OF EVIDENCE: 4. PMID: 29789235 [PubMed - as supplied by publisher]
CONCLUSIONS: In this study obese men do not appear to have a significant increase in risk of PSMs at RP compared to lean and overweight men when operated by a minimally invasive approach. The magnified vision and increased access to the pelvis allowed by a laparoscopic and robotic-assisted approach may be accountable for our findings. Larger studies are needed to validate our results. LEVEL OF PROOF: 4. PMID: 29789234 [PubMed - as supplied by publisher]
Is active surveillance for low-risk prostate cancer preferred in men who strongly want to preserve sexual function?Journal of the National Cancer Institute
Publication date: Available online 24 May 2018 Source:Journal of Applied Biomedicine Author(s): Patrícia Borba Martiny, Diego Duarte Alcoba, Brasil Silva Neto, Paulo Costa Carvalho, Ilma Simoni Brum Prostate cancer (PCa) is the second most frequent cancer in men worldwide. Distinguishing between the nonaggressive and aggressive forms of this disease is difficult, and a means to better characterize molecular patterns that could aid in diagnosis is urgently needed. Here, we compare the proteomic profiles of PCa and benign prostatic hyperplasia (BPH) in an effort to elucidate underlying mechanisms of oncogenesis. We c...
Publication date: Available online 24 May 2018 Source:European Urology Author(s): Giovanni Lughezzani, Nicolo’ Maria Buffi, Massimo Lazzeri
Publication date: Available online 24 May 2018 Source:European Urology Author(s): Vincenza Conteduca, Giorgia Gurioli, Ugo De Giorgi
Erleada (apalutamide) is the first treatment approved for nonmetastatic, castration-resistant prostate cancer.If patients prescribed apalutamide are also taking other drugs metabolized by the same cytochrome P-450 isoenzyme systems, the circulating levels of apalutamide may be altered.